However, approximately 90% of PAAD are ductal adenocarcinomas with KRAS mutations as the primary driver, which are typically characterized by fibrous tissue hyperplasia and reduced vascularity, which in turn leads to immunosuppression and resistance to chemotherapy and immunotherapy (43). The gene discussed is KRAS; the disease is pancreatic adenocarcinoma.